Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29381779 | 1.00 | POLB (0.51) | POLBMAPTMEN1KMT2APIN1 | |
| SCHEMBL31197366 | 0.98 | POLB (0.50) | POLBMAPTMEN1KMT2APIN1 | |
| Ammonia Solution, Strong SCHEMBL27736895 | 0.98 | POLB (0.50) | POLBMAPTMEN1KMT2APIN1 | |
| Hydrochloric Acid SCHEMBL3867195 | 0.98 | POLB (0.50) | POLBMAPTMEN1KMT2APIN1 | |
| SCHEMBL15923787 | 0.94 | POLB (0.46) | POLBMAPTMEN1KMT2APIN1 | |
| SCHEMBL6214746 | 0.84 | CYP1A2 (0.41) | POLBMAPTMEN1KMT2APIN1 | |
| SCHEMBL405386 | 0.83 | TSHR (0.47) | POLBMAPTMEN1KMT2ATSHR | |
| SCHEMBL29742161 | 0.83 | TSHR (0.47) | POLBMAPTMEN1KMT2ATSHR | |
| SCHEMBL15923304 | 0.81 | MAPT (0.40) | POLBMAPTMEN1KMT2APIN1 | |
| SCHEMBL16512770 | 0.81 | PIN1 (0.48) | MAPTMEN1KMT2APIN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 905 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112979546-B | Butyrylcholine esterase selective inhibitor and preparation method and application thereof | 中国药科大学 | 2023-01-31 | — | — | CN | claimed |
| CN-113461679-B | Synthesis of benzazepine isatin compound | 石药集团中奇制药技术（石家庄）有限公司 | 2022-09-30 | — | — | CN | claimed |
| CN-113461679-A | Synthesis of benzazepine isatin compound | 石药集团中奇制药技术（石家庄）有限公司 | 2021-10-01 | — | — | CN | claimed |
| CN-112979546-A | Butyrylcholine esterase selective inhibitor and preparation method and application thereof | 中国药科大学 | 2021-06-18 | — | — | CN | claimed |
| CN-110693850-A | Preparation method of imiquimod chitosan nanoparticles | 湖北科益药业股份有限公司 | 2020-01-17 | — | — | CN | claimed |
| CN-104402878-A | Preparation method of imiquimod | TIANFANG PHARMACEUTICAL CO LTD | 2015-03-11 | — | — | CN | claimed |
| CN-88102417-A | PHARMACEUTICAL COMPOSITION | — | 1988-11-09 | — | — | CN | claimed |
| EP-0288072-A2 | 3-Amino-4-(ethylthio)-quinoline or its acid addition salts for use as medicament and medicament containing it | EGIS GYOGYSZERGYAR (HU) | 1988-10-26 | — | — | EP | claimed |
| JP-3027381-A | — | — | None | — | — | JP | disclosed |
| JP-11269177-A | — | — | None | — | — | JP | disclosed |
| US-20260116880-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2026088120-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4178676-B1 | N-1 BRANCHED IMIDAZOQUINOLINES, CONJUGATES THEREOF, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | AMBRX, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-4444584-A | Ethyl 2[4-(7-chloroquinolin-3-yloxy)phenoxy]propionate, the N-oxide, and herbicidal compositions and methods employing them | ICI AUSTRALIA LIMITED (AU) | 1984-04-24 | — | — | US | disclosed |
| EP-0098751-A2 | Quinolinyloxy(amino)phenols and alkoxyphenyloxy(amino)quinolines | ICI AUSTRALIA LIMITED (AU) | 1984-01-18 | — | — | EP | disclosed |
| EP-0060429-A1 | Dichloroquinoline derivatives, their preparation and their use as herbicides | BASF Aktiengesellschaft (DE) | 1982-09-22 | — | — | EP | disclosed |
| US-4303660-A | ANALGESICS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1981-12-01 | — | — | US | disclosed |
| EP-0029319-A2 | Quinolinyloxy(amino)phenoxyalkane carboxylic acid derivatives, process for their synthesis, herbicidal compositions containing them and their use as herbicides | ICI AUSTRALIA LIMITED (AU) | 1981-05-27 | — | — | EP | disclosed |
| US-3873542-A | 3-Amino-as-triazino{8 6,5-c{9 quinoline and its 1-oxide, and a process for the preparation thereof | EGYT GYOGYSZERVEGYESZETI GYAR | 1975-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116880-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | TLR7, TLR8, TLR9 | POLB 3915/4885MAPT 3673/4885MEN1 3676/4885 |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | TLR3, TLR2, TLR1 | POLB 626/4885MAPT 1438/4885MEN1 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.